Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer.

Recurrent Prostate Cancer Clinical Trial

Official title:

A Phase 3, Non-randomized, Open Label, Multi-centre Clinical Trial to Investigate the Safety and Efficacy of [18F]PSMA-1007 Injection in Men With Suspected Persistent or Recurrent Prostate Cancer.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04644822
• Other study ID #: CPD-002
• Status: Completed
• Phase: Phase 3
• Start date: December 21, 2020
• Est. completion date: January 8, 2024

Study information

• Verified date: February 2024
• Source: Centre for Probe Development and Commercialization
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, Phase 3 non-randomized, open label, multi-centre clinical trial to assess the safety and efficacy of [18F]PSMA-1007 Injection (investigational product or IP) in evaluating men with suspected persistent or recurrent disease (i.e., with biochemical failure), but with negative or equivocal conventional re-staging imaging (bone scan [BS] and computed tomography [CT] of abdomen and pelvis).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: January 8, 2024
• Est. primary completion date: January 8, 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Able to read and speak in English and provide informed consent

2. Male, Age = 18 years

3. Prior primary treatment for prostate cancer with curative intent such as radical prostatectomy or radiotherapy for localized prostate cancer or other local or focal ablative therapy of the prostate

4. Not currently on systemic therapy (adjuvant or salvage) including androgen deprivation therapy

5. Suspected progressive or persistent disease after primary treatment for prostate cancer and biochemical failure (BF) with current management according to the

following:

1. Following primary radical prostatectomy (with or without adjuvant or salvage radiotherapy to the prostate bed/pelvis), where BF is defined as rising PSA on at least 2 occasions measured at least 1 month apart and with the most recent PSA measured within 3 months prior to enrollment at > 0.1 ng/mL

2. Following primary radiotherapy (with either brachytherapy, external beam radiotherapy or combined brachytherapy and radiotherapy) for localized disease, where BF is defined according to the Phoenix Definition, which is rising PSA on at least 2 occasions measured at least 1 month apart and with the most recent PSA measured within 3 months prior to enrollment greater than the nadir PSA + 2.0 ng/mL

3. Following primary ablative therapy to the prostate given with radical intent such as prior HIFU (high intensity focused ultrasound) or cryotherapy or other ablative energy therapy with biochemical failure as defined by the Stuttgart Criteria (nadir PSA + 1.2 ng/mL within 3 months prior to enrollment )

6. If PSA > 10 ng/mL, conventional imaging consisting of bone scan and CT scan within 3 months prior to consent that is either negative or equivocal.

7. Male subjects must be either:

1. Documented by medical records or physician's note to be surgically sterile or,

2. If capable of fathering a child, commit to the use of a barrier method of contraception, or agree to remain abstinent for 48 hours post-administration of the IP

8. Male subjects must agree to not donate sperm for 48 hours post-administration of the IP

9. Willing to participate in the study, is expected to be compliant, able to cooperate with study procedures, and have a high probability of completing the study in the opinion of the investigator

10. Vital sign results at Visit 1 and (pre-IP administration) at Visit 2 are within normal ranges, or if outside the normal ranges the results are judged by the investigator to not be clinically significant

11. Karnofsky performance status 70 or better (ECOG 0, 1)

12. Life expectancy of 6 months or more as judged by the investigator

13. Patient is medically suitable for salvage therapies

Exclusion Criteria:

1. Prostate cancer with significant sarcomatoid or spindle cell or neuroendocrine small cell components

2. Prior PSMA PET scan within 6 months of enrolment

3. Use of any other investigational medication or devices within 30 days prior to Visit 1

4. Known allergies or sensitivity to any component of the investigational product used in this study

5. Received significant ionizing radiation exposure, as judged by the Investigator, including from diagnostic or therapeutic radiopharmaceuticals used in clinical trials or for routine medical examinations, in the last 12 months

6. Undergoing ongoing occupational monitoring for radiation exposure

7. Clinically active, unstable, serious, life-threatening medical condition or disease that is, in the opinion of the Investigator, inadequately treated and/or where study participation may compromise the clinical management of the subject, or any other reason that makes the subject unsuitable to participate in this study

8. The participant has a history of alcohol or substance abuse

9. Patient cannot lie still for at least 30 minutes or comply with imaging procedure

Related Conditions & MeSH terms

• Prostate Cancer Recurrent
• Prostatic Neoplasms
• Recurrence
• Recurrent Prostate Cancer

Intervention

Diagnostic Test:
• [18F] PSMA-1007 Injection
a novel [18F] PSMA radiotracer that is highly selective for PSMA.

Locations

Country	Name	City	State
Canada	London Health Sciences Centre	London	Ontario
Canada	University Health Network - Princess Margaret Cancer Centre	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Centre for Probe Development and Commercialization	McDougall Scientific Ltd.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Percentage of patients with detectable disease relative to PSA levels		2 months
Other	Imaging concordance (sensitivity, specificity, PPV, NPV) based on [18F]PSMA-1007 PET/CT (at the regional level) compared with clinical outcome information (e.g., conventional imaging, clinical outcome surrogate or histopathologic correlate)		8 months
Primary	Primary Endpoint:	• Imaging concordance (sensitivity, specificity, PPV, NPV) will be calculated by comparing presence or absence of disease based on PSMA-PET (at the patient level) compared with clinical outcome information (e.g., conventional imaging, clinical outcome surrogate or histopathologic correlate)	8 months
Secondary	Safety: Occurrence of AEs, SAEs, and changes from baseline in vital signs		2 days
Secondary	Percentage of patients identified with recurrent disease using [18F]PSMA-1007		2 months
Secondary	Frequency with which [18F]PSMA-1007 PET/CT results lead to a change in recommended management		2 months